NASDAQ$IDYA
IDEAYA Biosciences Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
IDEAYA Biosciences reported financial results for the first quarter ended March 31, 2024 and provided a business update.
IDEAYA Biosciences reported a net loss of $39.6 million for the first quarter ended March 31, 2024. As of March 31, 2024, IDEAYA had cash, cash equivalents and marketable securities totaling $941.4 million.
- ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored trial and regulatory guidance both in H2 2024
- Selected move-forward Phase 2 dose for IDE397 in MTAP squamous NSCLC, based on clinical efficacy observed in this indication, including multiple PRs by RECIST 1.1; and multiple PRs by RECIST 1.1 have also been observed in MTAP bladder cancer
- Enrollment is ongoing in the IDE397 and AMG 193 Phase 1 dose escalation and targeting development of joint Amgen / IDEAYA publication strategy in 2024
- First-patient-in (FPI) for Phase 1 trial of IDE397 in combination with Gilead’s Trodelvy® in MTAP bladder cancer targeted mid-year 2024
Headline financials
Revenue & EPS history
IDEAYA · Revenue · Quarterly
$0
Revenue by segment
IDEAYA · $8.04M total across 1 segment · Q3 2023
- Collaboration Revenue$8.04M—100.0%
Forward guidance
IDEAYA is targeting several milestones in the second half of 2024, across its clinical programs and next-generation pipeline.
Tailwinds
- Targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored trial and regulatory guidance both in H2 2024
- Targeting initial Phase 2 expansion for IDE161 in HRD solid tumors in H2 2024
- Targeting Phase 1 FPI for IDE161 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® in endometrial cancer in H2 2024
- Targeting Werner IND-filing with GSK in H2 2024, representing 5th potential first-in-class clinical program
- Targeting MTAP development candidate in H2 2024 to enable wholly-owned IDE397 combination
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+1.4%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+6.7%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+40.5%
Q3 2019
Best reaction
-31.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.3% | -1.9% | +1.2% | |
| Q4 2025 | +1.6% | +5.6% | +7.7% | |
| Q3 2025 | -2.7% | -3.6% | +14.8% | |
| Q1 2025 | +2.9% | +10.6% | +28.1% | |
| Q4 2024 | -5.4% | -6.9% | -15.4% | |
| Q3 2024 | +3.4% | +9.4% | -0.9% | |
| Q2 2024 | -3.1% | +2.4% | +1.0% | |
| Q1 2024 | -3.9% | -4.5% | -8.0% | |
| Q4 2023 | -6.0% | -2.7% | -3.2% | |
| Q3 2023 | +6.9% | +1.6% | +8.1% | |
| Q2 2023 | +1.2% | +3.3% | +12.9% | |
| Q1 2023 | +15.6% | +10.2% | +31.5% | |
| Q4 2022 | +2.1% | -8.7% | -16.0% | |
| Q3 2022 | -3.4% | -1.8% | -2.5% | |
| Q2 2022 | -31.4% | -34.8% | -20.1% | |
| Q1 2022 | +13.0% | +26.4% | +48.4% | |
| Q4 2021 | -2.2% | +3.8% | -11.1% | |
| Q3 2021 | +3.9% | +0.8% | -4.1% | |
| Q2 2021 | -3.5% | +1.0% | +14.1% | |
| Q1 2021 | +7.8% | +1.7% | +12.5% | |
| Q4 2020 | -8.2% | -2.8% | -15.9% | |
| Q3 2020 | +2.5% | +6.3% | +9.3% | |
| Q2 2020 | -1.2% | -1.7% | +4.8% | |
| Q1 2020 | -9.4% | -0.6% | -5.3% | |
| Q4 2019 | +13.6% | +14.9% | +40.8% | |
| Q3 2019 | +40.5% | +30.6% | +29.6% | |
| Q2 2019 | +6.0% | -1.5% | +19.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro